
    
      This Phase 1 study will enroll up to approximately 86 evaluable adult subjects with
      refractory cancer (solid tumors) regardless of diagnosis. Subjects may be enrolled into the
      following cohorts:

      The trial will consist of a 3+3 dose escalation that will evaluate different combination dose
      levels of AGEN2373 monotherapy and in combination with Balstilimab (AGEN2034). Each subject
      will stay on the dose level at a schedule assigned at trial entry. Subjects can be replaced
      for any reason other than a DLT. Subjects will receive treatment for â‰¤ 2 years or until PD,
      unacceptable toxicity, or any criterion for stopping the study drug or withdrawal of trial
      occurs.
    
  